Analysts expect that Waters Co. (NYSE:WAT) will post sales of $702.52 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Waters’ earnings, with the lowest sales estimate coming in at $690.71 million and the highest estimate coming in at $713.00 million. Waters posted sales of $687.28 million in the same quarter last year, which suggests a positive year-over-year growth rate of 2.2%. The business is scheduled to report its next earnings report on Tuesday, January 22nd.
On average, analysts expect that Waters will report full year sales of $2.41 billion for the current year, with estimates ranging from $2.40 billion to $2.42 billion. For the next financial year, analysts forecast that the firm will post sales of $2.50 billion, with estimates ranging from $2.44 billion to $2.54 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Waters.
Waters (NYSE:WAT) last posted its quarterly earnings results on Tuesday, October 23rd. The medical instruments supplier reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.90 by $0.02. Waters had a return on equity of 30.68% and a net margin of 2.32%. The company had revenue of $578.02 million during the quarter, compared to analysts’ expectations of $587.43 million. During the same quarter in the previous year, the firm earned $1.77 EPS. Waters’s revenue was up 2.2% on a year-over-year basis.
Shares of Waters stock traded down $1.69 during trading on Tuesday, reaching $196.08. 518,582 shares of the company’s stock were exchanged, compared to its average volume of 564,824. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.93 and a current ratio of 6.63. Waters has a 1-year low of $167.93 and a 1-year high of $220.20. The stock has a market capitalization of $15.12 billion, a P/E ratio of 26.18, a price-to-earnings-growth ratio of 2.39 and a beta of 0.94.
In other Waters news, Director Thomas P. Salice sold 3,500 shares of the stock in a transaction that occurred on Wednesday, October 31st. The stock was sold at an average price of $192.00, for a total value of $672,000.00. Following the transaction, the director now owns 20,911 shares in the company, valued at $4,014,912. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Elizabeth B. Rae sold 4,000 shares of the stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $190.62, for a total value of $762,480.00. Following the completion of the transaction, the senior vice president now owns 9,443 shares in the company, valued at approximately $1,800,024.66. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,500 shares of company stock worth $3,031,840. Corporate insiders own 0.98% of the company’s stock.
Large investors have recently made changes to their positions in the business. Marshall Wace LLP bought a new position in Waters in the second quarter worth approximately $239,000. Wells Fargo & Company MN raised its stake in shares of Waters by 40.5% in the second quarter. Wells Fargo & Company MN now owns 336,181 shares of the medical instruments supplier’s stock worth $65,081,000 after purchasing an additional 96,866 shares during the last quarter. Fundsmith Equity Fund L.P. purchased a new stake in shares of Waters in the second quarter worth approximately $915,485,000. Ontario Teachers Pension Plan Board raised its stake in shares of Waters by 62.9% in the second quarter. Ontario Teachers Pension Plan Board now owns 155,990 shares of the medical instruments supplier’s stock worth $30,198,000 after purchasing an additional 60,239 shares during the last quarter. Finally, Mackay Shields LLC raised its stake in shares of Waters by 50.2% in the second quarter. Mackay Shields LLC now owns 20,112 shares of the medical instruments supplier’s stock worth $3,894,000 after purchasing an additional 6,724 shares during the last quarter. Institutional investors and hedge funds own 99.26% of the company’s stock.
Waters Company Profile
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Featured Article: How are institutional investors different from individual investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.